Aims: Optimal diabetes care requires clear understanding of the incidence of hypoglycaemia in real-world clinical practice. Current data on hypoglycaemia are generally limited to those reported from randomised controlled clinical trials. The Hypoglycaemia Assessment Tool (HAT) study, a non-interventional real-world study of hypoglycaemia, assessed hypoglycaemia in 27 585 individuals across 24 countries. The present study compared the incidence of hypoglycaemia from the HAT study with other similarly designed, large, real-world studies.
| INTRODUCTION
The ultimate goal of glycaemic management in both type 1 (T1D) and type 2 diabetes (T2D) is achievement of individualized glycaemic goals without hypoglycaemia, which remains a common and acute complication with antidiabetic medications, particularly exogenous insulin therapy. In T1D and T2D, hypoglycaemia can limit the glycaemic control that patients achieve and, therefore, undermine the goal of preventing long-term complications. [1] [2] [3] [4] [5] Furthermore, hypoglycaemia has a well-established significant negative impact on well-being, productivity and quality of life (QOL). 6 Recent studies have confirmed that, in addition to decreased overall health-related QOL, hypoglycaemia can negatively impact physical and mental well-being, limit mobility, lead to anxiety and depression, interfere with social activities, result in missed work (absenteeism), impair performance while at work (presenteeism) and decrease overall work productivity. [7] [8] [9] [10] [11] [12] In addition to an economic burden for patients, hypoglycaemia is associated with increased healthcare resource utilization and health-economic burden. [7] [8] [9] Severe hypoglycaemia events frequently result in emergency/ambulance calls and hospital treatment and, hence, incur substantial healthcare costs. [11] [12] [13] It is important to have a clear understanding of the true incidence of hypoglycaemia in order to individually tailor glycated haemoglobin (HbA1c) targets, to provide optimal clinical care, to facilitate healthcare resource planning and to develop targeted hypoglycaemia prevention strategies. 14 The incidence of hypoglycaemia is generally reported from randomized controlled trials, from which patients with comorbidities or frequent severe hypoglycaemia are typically excluded, and many of the studies have a treat-to-target design. Consequently, the application of findings to real-world settings may be limited, and the prevalence and incidence of hypoglycaemia in clinical trials may not reflect those in real-world clinical practice. 14 The Hypoglycaemia Assessment Tool (HAT) study is one of the largest real-world global hypoglycaemia studies conducted to date.
HAT is a large, international (27 585 patients with T1D or T2D in 24 countries across Europe, Asia, North America and South America), non-interventional, 6-month retrospective, 1-month prospective study to determine the extent of hypoglycaemia in both T1D and T2D
in clinical practice. 15 This literature review aimed to collate and evaluate the incidences of hypoglycaemia reported in current literature concerning real-world insulin-treated diabetes populations. Findings from similarly designed large observational studies identified in a literature search were to be compared with those of the HAT study with a view to explaining any observed differences.
| MATERIALS AND METHODS

| Search strategy
We conducted an electronic literature search of the PubMed database from January 1995 to December 2017 to identify population-based studies, excluding clinical trials and reviews, of individuals treated with insulin, with a design similar to that of the HAT study (clinicaltrials.gov NCT02240355), in which the proportion of individuals experiencing hypoglycaemia, or the rates of hypoglycaemic events, were reported by patient questionnaires, diaries or patient records.
The search terms used were "diabetes OR diabetic, AND hypoglycemia OR hypoglycaemia OR hypoglycemic OR hypoglycaemic, AND survey OR report OR questionnaire, AND rate OR incidence OR frequency OR risk." We included observational studies in which the study population was a defined general population with T1D and/or T2D. We did not apply any restrictions relating to language or classification, definition or measurement of hypoglycaemia.
Following removal of duplicate publications, titles and abstracts were reviewed to identify studies that met the inclusion criteria.
Where it was unclear from the abstract whether the inclusion criteria were met, the full article was retrieved and reviewed. The reporting of data regarding the following criteria was used to determine study relevance: patient self-reported hypoglycaemia; incidence rates; observational studies and surveys; patient awareness of hypoglycaemia; fear of hypoglycaemia; experience of hypoglycaemia and its impact on QOL, productivity and healthcare utilization.
| Data extraction
Where data were available, we extracted the following for each study:
country, number of participants (T1D and T2D), type of insulin therapy and duration of use, disease duration, HbA1c levels (% and mmol/ mol), patient inclusion criteria, definitions of hypoglycaemia if available/documented and incidence of hypoglycaemia (overall, mild/nonsevere, severe and nocturnal). Where data were not reported, no attempt was made to contact the authors of the individual publications to retrieve additional data.
| Data analysis
Relevant data were summarized and descriptive comparisons were made among studies, including the HAT study. The co-primary objectives of this literature review were to explore rates of hypoglycaemia (overall, severe and nocturnal) in individuals with T1D and/or T2D within population-based studies and compare the results with hypoglycaemia data from the prospective HAT study, both global and regional analyses.
3 | RESULTS
| Identification of studies
Results relating to the identification process for eligible studies are summarized in Figure 1 . PANORAMA, 20 JADE, 21 survey of insulin adherence, 22 the single centre study in India, 23 and the ICU study 24 primarily reported hypoglycaemia prevalence in terms of the proportion of participants reporting hypoglycaemia, rather than rates in events per patient-year (PPY);
thus, these studies are reported separately.
| Summary of studies included in the analysis
An overview of the studies identified is provided in Table S1 . All reported data are observational, with 13 studies being prospective, nine being retrospective and two, including the HAT study, using a mixed methods, prospective/retrospective design. In total, the studies ). Studies variously reported rates of self-treated, overall, mild/moderate, mild/non-severe and nocturnal, mild/non-severe and severe, mild/non-severe and severe and nocturnal, overall and severe and nocturnal, overall and mild/non-severe and severe and nocturnal hypoglycaemia and severe hypoglycaemia. Definitions of hypoglycaemia varied among studies (Table S2 ).
3.3 | Evaluation of the HAT study and comparative real-world clinical study designs Similar to the HAT study, the duration of prior insulin therapies in these studies was generally more than 1 year, although some studies, such as SOLVE, examined patients for whom basal insulin was initiated. Some studies included patients with substantially longer exposure. For example, the GAPP2 study in the UK included patients with up to 20 years of insulin use. 16 With the exception of the UK Hypoglycaemia study, which included patients with T1D duration of up to were also generally comparable.
The definitions of hypoglycaemia varied widely among studies (Table S2) ) and one study from North America (GAPP2 Canada 5 ).
Data on hypoglycaemia should be evaluated in the context of HbA1c. In many studies this was not reported, but there was very little variation across studies in the values that were reported (Table S1 ).
3.4 | Proportions and rates of hypoglycaemia in the HAT study vs other real-world studies Data for hypoglycaemia rates in T1D and T2D are given in Tables 1   and 2 , respectively, with the studies reporting rates, expressed here as events PPY, separated from those reporting only the proportion of patients affected. Both parameters were used in the HAT study. As expected, the rates of overall, mild/non-severe, severe and nocturnal hypoglycaemia in patients with T1D were higher than those in patients with T2D in all studies. Across studies, reported rates ranged in Japan, the frequency of hypoglycaemia (events/month) was 7.7 AE 9.9 in patients with T1D and 1.3 AE 3.3 in patients with T2D. 25 The data concerning proportions affected are potentially less informative, as these will be impacted by the time interval over which the evaluation was made; however, the proportions in the HAT study, real-world studies (~20-125 events PPY) ( Table 1) . From European data in the global HAT study, Eastern and North European rates of non-severe hypoglycaemia were also within range at 66.9 PPY and 91.6 PPY, respectively. Overall rates in the PREDICTIVE trial were lower; however, in that study, the blood glucose definition of hypoglycaemia was less than 2.8 mmol/L (50 mg/dL), whereas, in the HAT study, various definitions were used and in the GAPP2 study, it was undefined, and in other studies, such as HypoAna, it was less than 3.9 mmol/L (≤70.2 mg/dL).
| T1D: Severe hypoglycaemia
The rate of severe hypoglycaemia in the global HAT dataset was 4.9 events PPY, which is within the range of the other European studies (0.7-5.8 events PPY) ( The PREDICTIVE study also reported lower rates than the HAT study, but used a more stringent definition of severe hypoglycaemia. While both the HAT and HypoAna studies defined severe hypoglycaemia as events requiring third-party assistance to administer carbohydrate, glucagon or other resuscitative action, the PREDICTIVE study required third-party intervention along with a blood glucose reading less than 2.8 mmol/L (50 mg/dL) or reversal of symptoms after food intake, glucagon or intravenous glucose.
| T1D: Nocturnal hypoglycaemia
Only three studies reported nocturnal hypoglycaemia in T1D. The rates in the HAT study (11.3 events PPY) were higher as compared with the HypoAna study (8.5 non-severe, 2.6 symptomatic and 3.3 asymptomatic events PPY) and the PREDICTIVE study (3.6 events PPY) ( Table 1 ). According to the HAT study, nocturnal hypoglycaemia rates in Northern Europe were higher than those reported globally, at 12.9 PPY, and in Eastern Europe rates were lower, at 9.8 PPY.
| T2D: Overall and mild/non-severe hypoglycaemia
Rates of overall and mild/non-severe hypoglycaemia were similar, between 19 and 40 events PPY, in the HAT 19 and GAPP2 21 studies and in two European self-reported studies. 4, 29 According to the HAT study, Northern and Eastern Europe rates of non-severe hypoglycaemia were 18.1 PPY and 23.7 PPY, respectively. Other studies, such as PREDICTIVE 27 , A1chieve 29 and SOLVE, 37 reported lower rates of 1.3 to 3.1 events PPY. These lower rates may reflect the fact that, in the A1chieve study, 67.2% of patients were insulin-naïve at baseline, whereas 100% of participants in the SOLVE study were insulin naïve at baseline. Hence, the lower rates of overall hypoglycaemia in those studies vs the HAT and GAPP2 studies may reflect different participant populations. As for the PREDICTIVE trial, the comparatively lower rates may reflect more stringent hypoglycaemia criteria as compared to the HAT and GAPP2 studies.
| T2D: Severe hypoglycaemia
Rates of severe hypoglycaemia in T2D were uniformly low across most studies, ranging from 0.0046 to 0.7 events PPY, and were highest in the HAT study, at 2.5 events PPY. In Europe, rates were high at 1.3 PPY (Northern Europe) and at 2.2 PPY (Eastern Europe). In the HAT study, only 0.237 events PPY required hospitalization. Differences among the rates of severe hypoglycaemia probably reflect the differences among studies, in the study populations and in the definitions of hypoglycaemia used, as discussed above.
| T2D: Nocturnal hypoglycaemia
Rates of nocturnal hypoglycaemia were higher in the HAT (3.7 events PPY) and GAPP2 (9.7 events PPY) studies than in the other studies that reported rates, including PREDICTIVE, A1chieve, PRESENT and SOLVE (0.4-0.7 events PPY). Rates were also high in European datasets from the HAT study; in Northern Europe, rates were 3.7 PPY and in Eastern Europe, rates were 4.0 PPY. This is perhaps not surprising,
given the different populations included in the various studies. For example, the GAPP2 study, 21 which had the highest rates of nocturnal hypoglycaemia, included participants who had undergone more than 5 years of insulin therapy, whereas studies with the lower rates, including the PRESENT and SOLVE studies, included insulin-naïve participants.
| DISCUSSION
This review of 24 real-world studies highlights the fact that reported rates of overall, mild/non-severe, severe and nocturnal hypoglycaemia are variable; however, most of this variability appears to be explained by the type of participants included and by differences among studies in the definitions of hypoglycaemia. Different data collection methods (questionnaires, diaries and patient records) also contribute to some variation in the level of detail available and to the reported rates of hypoglycaemia. Recently, attention has been focused on the different definitions that confound the ability to compare and translate study data. This has led to the release of a joint ADA/EASD statement from the International Hypoglycaemia Study Group calling for uniform definitions to be used in clinical trials. 39 Clearly, this approach would also contribute to the ability to draw meaningful comparisons across data from real-world and epidemiological studies. Another source of variation in reported rates may arise from differences between retrospective and prospective reporting, whereby retrospective reporting is potentially less accurate as the result of memory bias and inconsistency in methods of data collection. Global data, from studies such as GAPP2 and HAT, provide initial indications that rates of hypoglycaemia in some regions of the world may be higher than previously suggested, but further regional real-world studies are required to confirm this.
| Relationship to other literature
Other than the individual studies identified in this analysis, there is a paucity of literature focusing on hypoglycaemia rates among insulintreated patients in real-world settings. However, a recent systematic review and meta-analysis of population-based studies involving patients with T2D concluded that hypoglycaemia is highly prevalent among insulin-treated patients with T2D. The meta-analysis described a high degree of heterogeneity among studies, and estimated an incidence of 23 events PPY for mild/moderate hypoglycaemia, and one event PPY for severe hypoglycaemia. The rate for mild/moderate hypoglycaemia was comparable to that reported in the HAT study (19.3 overall events PPY) but the rate for severe hypoglycaemia was lower than that reported in the HAT study (2.5 severe events PPY).
14 While the HAT study included a truly global population, no previous hypoglycaemia incidence data were available for many participants. A further finding of the literature review was the limited global reach of other real-world studies. Most studies, particularly in T1D, were focussed on Europe and North America. The exceptions were the GAPP2 (Global), A1chieve (Asia, North Africa, Middle East/Gulf, Latin America and Russia) and PRESENT studies, a single-centre study (India), the COMPASS and DSP China studies (China), the JADE study (Hong Kong), a basal insulin dose-timing study in T2D (Japan) and a self-reported insulin adherence study in T1D and T2D (Brazil). Therefore, in order to identify regional differences in hypoglycaemia rates, particularly in T1D, further real-world global studies are required to identify the explanation for variations among regions, and intervention studies are required to reduce the high rates of hypoglycaemia.
| Study limitations
Comparison of data from the component studies is not straightforward because of differences in inclusion criteria and definitions of hypoglycaemia, as well as differences in reporting/documentation mechanisms. There are multiple definitions of hypoglycaemia and conflicting data concerning the incidence of hypoglycaemia available in the scientific literature. 40 Combined with the fact that hypoglycaemic events often go undetected, for a number of reasons, studies with patient-reported data will unavoidably have variable outcomes if hypoglycaemia events are not confirmed with blood glucose measurements. 40 Recall is an often-used but potentially inaccurate mechanism to document hypoglycaemic events and a patient diary provides a more realistic mechanism to record the incidence of hypoglycaemia. A further confounding factor might be an unequal use of different insulin regimens (eg, insulin analogues vs more traditional products) and density of glucose measurement among studies. Limitations of the methodology of this literature review are that it includes only publications that are listed in PubMed and the fact that results were reviewed and included/excluded by multiple individuals.
| Implications of the study
The main clinical implication of this analysis is that hypoglycaemia is more prevalent in real-world insulin-treated diabetes cohorts than is indicated by data from randomized controlled trials. This is important because hypoglycaemia has a significant impact on glycaemic control and health-related QOL. Data from the HAT study broadly support other studies in highlighting this issue. Concerning T1D, the HAT study confirmed the seriousness of the hypoglycaemia challenge facing individuals, with overall rates of 73.3 events PPY, approximately six events each month, five severe events PPY and 11 nocturnal events PPY. Individuals with insulin-treated T2D will probably experience an average of 19 hypoglycaemic events overall annually, including 2.5 severe and 3.7 nocturnal events according to data from the HAT study.
The current study highlights the need for uniform definitions of hypoglycaemia, and for these uniform definitions to be used in real-world studies, in order to draw accurate conclusions from the literature base. Standardization of hypoglycaemia definitions would be particularly useful in making comparisons among regions, with a view to informing the construction of regional guidelines. However, a further implication of our literature review is that there is a need for further study of hypoglycaemia rates in cohorts beyond Europe and North America to support regional recommendations.
In conclusion, data from the HAT study contributes to the existing literature by demonstrating that the global incidence of hypoglycaemia is high in all insulin-treated patient groups. There are inconsistencies among studies in the rates reported, but these are explained mostly by patient characteristics and by study methodology, leaving an overall picture of a globally consistent clinical problem. We therefore suggest that the goal of reducing hypoglycaemia should be a target for continued educational and evidence-based pharmacological interventions.
